AUPH Live signals | Maximize Profits with Getagraph.com

BUY 101722 min ago

@ $7.86

Issued: 14 Feb 2024 @ 13:50

Return: -35.96%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -1.44 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	785 988
Average Volume	2.09M
Market Cap	727.43M
EPS	$0 ( 2024-02-15 )
Next earnings date	( $-0.170 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.31
ATR14	$0.00500 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Greenleaf Peter	Sell	126 981	Common Stock
2024-03-06	Miller Joseph M	Sell	34 811	Common Stock
2024-03-06	Donley Matthew Maxwell	Sell	40 665	Common Stock
2024-03-06	Habig Scott Michael	Sell	17 777	Common Stock
2024-03-06	Robertson Stephen P.	Sell	57 745	Common Stock

INSIDER POWER
72.34
Last 95 transactions
Buy: 5 896 445 \| Sell: 560 044

Volume Correlation

Long: 0.17 (neutral)

Short: -0.41 (neutral)

Signal:(64.08) Neutral

Aurinia Pharmaceuticals Correlation

10 Most Positive Correlations
AVAC	0.953
HWEL	0.948
CIIG	0.947
AVEO	0.938
ARIZ	0.937
KVSA	0.934
FNVT	0.934
GRIL	0.932
GLLI	0.932
EMLD	0.93

10 Most Negative Correlations
GRIN	-0.949
LGHL	-0.948
VIEW	-0.945
TIVC	-0.939
BNTX	-0.937
XFOR	-0.931
VORB	-0.93
CUTR	-0.93
THTX	-0.927
LQDT	-0.925

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aurinia Pharmaceuticals Correlation - Currency/Commodity

0.73
( moderate )

0.64
( weak )

0.00
( neutral )

0.33
( neutral )

0.20
( neutral )

Aurinia Pharmaceuticals Financials

Annual	2023
Revenue:	$175.51M
Gross Profit:	$161.37M (91.94 %)
EPS:	$-0.540

Q4	2023
Revenue:	$45.10M
Gross Profit:	$39.70M (88.04 %)
EPS:	$-0.190

Q3	2023
Revenue:	$54.52M
Gross Profit:	$47.75M (87.58 %)
EPS:	$-0.0941

Q2	2023
Revenue:	$41.49M
Gross Profit:	$39.93M (96.23 %)
EPS:	$-0.0805

Financial Reports:

No articles found.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.